Browsing by Autor "Eugenio Arteaga"

Now showing 1 - 4 of 4

A specific, stable, and accessible LAMP assay targeting the HSP70 gene of Trypanosoma cruzi
(2025) Sneider Alexander Gutierrez Guarnizo; Luciana Basma; Shirley Equilia; Beth Jessy Condori; Edith Málaga; Siena Defazio; Eugenio Arteaga; Jean Karla Velarde; Mateo Obregón; Anshule Takyar
Diagnostic delays prevent most Chagas disease patients from receiving timely therapy during the acute phase when treatment is effective. qPCR-based diagnostic methods provide high sensitivity during this phase but require specialized equipment and complex protocols. More simple and cost-effective tools are urgently needed to optimize early Chagas disease diagnosis in low-income endemic regions. Here, we present a loop-mediated isothermal amplification (LAMP) that targets a highly conserved region in the HSP70 gene of Trypanosoma cruzi, the causative agent of Chagas disease. This assay demonstrates species-specific amplification across multiple parasite genetic lineages while maintaining stability after 2 hours of incubation and at least 8 months of storage at -20°C. Moreover, the assay is at least 12 times less expensive than the TaqMan qPCR that is currently routinely used for acute Chagas diagnostics. Population-based validation in 100 infants born to Chagas-positive mothers in Santa Cruz, Bolivia, yielded a specificity of 100% and sensitivity exceeding 77% when compared to a TaqMan qPCR that targets satellite DNA. This cost-effective assay holds promise for large-scale diagnosis of Chagas disease in endemic regions with limited resources.
A specific, stable, and accessible LAMP assay targeting the HSP70 gene of Trypanosoma cruzi
(American Society for Microbiology, 2025) Sneider Alexander Gutierrez Guarnizo; Beth Jessy Condori; Luciana Basma; Shirley Equilia; Edith Málaga; Siena Defazio; Eugenio Arteaga; Jean Karla Velarde; Mateo Obregón; Anshule Takyar
Chagas disease, caused by the parasite Trypanosoma cruzi, is a life-threatening illness that disproportionately affects resource-limited communities. Congenital Chagas disease, if diagnosed early, presents a unique opportunity for intervention, as treatment in newborns is highly effective with minimal side effects. However, early diagnosis is hindered by the high cost and limited availability of current molecular diagnostic methods in endemic regions. Our study introduces a simple, low-cost, and highly specific LAMP assay targeting the HSP70 gene of T. cruzi. This assay is user-friendly, stable under varying storage and incubation conditions, and designed for accessibility in underserved areas. By providing a detailed, open-access protocol and primers, we aim to facilitate the widespread adoption of this diagnostic assay, enabling earlier detection and treatment. This assay lays the groundwork for a new approach to Chagas disease management, potentially reducing the spread of Chagas disease and improving public health outcomes in vulnerable populations globally.
Hot flashes: a potential marker of deterioration of health-related quality of life
(Taylor & Francis, 2026) Juan E Blümel; María S. Vallejo; Peter Chedraui; Eugenio Arteaga; Félix Ayala; Ascanio Bencosme; Andrés Calle; Lucia Costa-Paiva; Maribel Dextre; Karen Díaz
Hot flush severity is a strong and independent determinant of HRQoL in midlife women. These findings underscore the need for systematic assessment and targeted management of vasomotor symptoms in routine care, supporting the hypothesis that hot flashes may be a clinical marker of systemic aging.
Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study
(Informa, 2020) Juan E. Blümel; Eugenio Arteaga; Sócrates Aedo; Jose Arriola‐Montenegro; Marcela López; Mabel Martino; Carlos Henrique Miranda; Octavio Miranda; Desireé Mostajo; Mónica Ñañez
Metformin may decrease cell senescence, including bone; hence we aimed at evaluating the association between metformin use and osteoporosis. This was a cross-sectional study carried out in 1259 Latin American adult women aged 40 or more who were not on anti-osteoporotic drugs, were on metformin and had a bone densitometry performed. Of the whole sample, 40.3% reported being on metformin (at least 1 year), 30.2% had type 2 diabetes mellitus and 22.6% had osteoporosis. Median (interquartile range) body mass index (BMI) for the whole cohort was 27.7 (4.6) kg/m2 and 30.2% had type 2 diabetes mellitus. Current use of hormone therapy, calcium, and vitamin D corresponded respectively to 10.7%, 47.7%, and 43.1% of all surveyed women. A logistic regression model was used to analyze the association of osteoporosis with various covariates incorporated into the model such as age (OR: 1.07, 95% CI: 1.05-1.09), BMI (OR: 0.92, 95% CI: 0.89-0.96) and metformin use (OR: 0.44, 95% CI: 0.32-0.59). Metformin use, regardless of the presence of type 2 diabetes or obesity, was associated with a lower risk of osteoporosis in adult women. We propose that one explanation for this observation could be the effect of the drug over cellular senescence.